Abstract-Microarray technology has enabled us to simultaneously measure the expression of thousands of genes. Using this high-throughput data collection, we can examine subtle genetic changes between biological samples and build predictive models for clinical applications. Although microarrays have dramatically increased the rate of data collection, sample size is still a major issue in feature selection. Previous methods show that microarray data combination is successful in improving selection when using z-scores and fold change. We propose a wrapper based gene selection technique that combines bootstrap estimated classification errors for individual genes across multiple datasets. The bootstrap is an unbiased estimator of classification error and has been shown to be effective for small sample data. Coupled with data combination across multiple data sets, we show that this metaanalytic approach improves gene selection.
Basic analysis methods for determining differential gene expression include fold change and t-test analysis. For example, the t-statistic for a gene with expression values x i in a dataset with two classes of sample sizes n 1 and differentially expressed genes are those with fold changes above a predetermined threshold. These statistical methods are limited in their effectiveness in finding differentially expressed genes because of the small sample size problem. Statistics such as mean and standard deviation of small sample data may be significantly biased, leading to false discoveries. Furthermore, biomarkers identified using t-test or fold change may not produce good predictive classifiers due to the non-Gaussian nature of gene expression. Alternative methods for identifying biomarkers that are also good predictive classifiers are called wrapper methods. These methods directly select candidate biomarkers that have high estimated predictive accuracy. For small sample data, various bootstrap and cross validation resampling methods have been shown to be accurate estimators of predictive performance [3] .
Several studies have examined methods for combining multiple microarray datasets. These methods include largescale data-mining, functional integration, ANOVA models, and effect size meta-analysis [4] [5] [6] [7] . Of particular interest is the study by Wang et al., which combines the fold change of genes between classes from three microarray datasets. Their computed statistic also takes into account the different variances within datasets [7] . Choi et al. computed a combined z-statistic and found that this combined statistic was able to identify more potential biomarkers than single dataset statistics [8] . None of these methods, however, have explored data combination using wrapper based gene selection. Such a method would have both the benefits of accurate identification of predictive genes from small datasets as well as increased sample size by combining multiple datasets.
The method we propose combines heterogeneous datasets by combining estimated classification errors for each gene across datasets and standardizing the combined error with a dataset-specific error variance. It is easily extended to any number of datasets and has the potential to increase the biological and statistical relevance of candidate biomarkers. II. METHODS
Combining Multiple Microarray Studies Using Bootstrap MetaAnalysis

A. Microarray Data
We use three groups of microarray datasets to test the bootstrap meta-analysis method. The first group includes samples from two renal cancer studies. Each study contains samples from clear cell, chromophobe, and oncocytoma renal cancer subtypes. Each study attempts to identify genes differentially expressed between the clear cell subtype and the group of both chromophobe and oncocytoma subtypes. There are a total of 45 clear cell samples, 10 chromophobe samples and 15 oncocytoma samples. Samples from both datasets are derived from oligo-based microarrays and contain 8793 genes [9, 10] . We split the larger dataset into two sets for a total of three small datasets of roughly equal size. This allows us to examine the effect of data combination on very small datasets.
The second group includes four prostate cancer datasets. Samples from two of the data sets are cDNA custom microarrays with 4530 common genes. Samples from the other two datasets are oligo-based microarrays with 5500 common genes. The final subset of common genes for all four datasets contains 2277 genes [11] [12] [13] [14] .
The third group includes two prostate cancer datasets with 12625 genes on oligo-based microarrays. Between the two datasets, there are a total of 113 tumor samples and 113 normal samples [15, 16] .
B. Feature Ranking
We use a wrapper based approach to rank genes by classification accuracy using bootstrap resampling. For each gene in dataset i with n samples, the bootstrap algorithm randomly selects n samples with replacement [17] . The unique n* samples selected by the bootstrap (n* < n) are designated as the training set for the support vector machine (SVM) classifier. The remaining n-n* samples are the testing set for the SVM. We repeat this for 100 iterations to compute the mean and variance of the classification error.
The SVM classifier predicts the class of new samples based on the expression values by computing a discriminating hyperplane that maximizes the margin between the two classes. The SVM is also advantageous in that we can assess the predictive performance of gene combinations. However, we limit the scope of this study to assume independence of genes. By comparing the SVM class output labels to the actual class labels, we can compute the mean classification error E at each iteration as:
where C i,SVM is the SVM predicted class label of the sample i of the test set and C i,actual is the true class label. Both C's are either 0 or 1 depending on the class. For a data set j and gene k, the errors computed across 100 bootstrap iterations has a mean of E j,k and variance of σ j,k 2 . The values of E j,k are bounded by [0, 1] . However, we want this distribution to be centered at 0 in order to compute a z-statistic describing the rarity of an observed error. Therefore, we subtract a datasetspecific no-information error rate (E j,noinfo ) from the estimated errors for all genes in the dataset. This error rate is typically 50% for binary classification problems with balanced sample sizes. In practice, sample sizes are rarely balanced and the no-information error rate usually becomes m/m t , where m is the number samples in the largest class and m t is the total number of samples. We may also compute E j,noinfo empirically after computing errors for all genes.
C. Data Combination
The combined, zero-centered classification error for a gene k across all datasets is [7] :
We assume that the combined, zero-centered classification errors for a gene in a group of datasets is normally distributed with mean equal to E comb,k and a variance of [7] :
We compute the combined z-score for each gene using
and select genes with significant p-values. We also compare gene selection using the combined z-score to individual dataset z-scores computed with
Negative z-scores correspond to small classification errors. These formulas have been adapted from Wang et al. [8] .
D. Feature Interpretation
In order to assess the benefits of data combination, we select genes from both individual and combined datasets using several statistical thresholds. Z-scores of differentially expressed genes are expected to be less than the threshold. The data combination method should identify different sets of genes compared to those identified by individual datasets. We interpret the biology of some of the genes that are selected by individual dataset analysis but not by combined dataset analysis. Conversely, we interpret genes that are selected by combined dataset analysis but not by individual dataset analysis. The biological validity of those genes in the context of their respective datasets is expected to elucidate the benefits gained from data combination.
III. RESULTS AND DISCUSSION
A. Significant Genes from Bootstrap Meta-Analysis
The scores for each gene combined across multiple datasets are approximately normally distributed, allowing us to easily select thresholds that correspond to specific confidences (Fig. 1, Fig. 2, Fig. 3) . There are differences between the features selected with individual datasets compared to the combined datasets (Table I, Table II, Table III ). In some cases, the combined dataset selects more features while in others, the combined dataset selects less. Data combination increases sample size and, presumably, confidence in our selection of differentially expressed genes. Consequently, the discrepancy in the selected genes between individual data and combined data methods should correlate with biological relevance. For example, if we identify differentially expressed genes from an individual dataset that we cannot identify from a combined dataset, we might find that that gene is not relevant to our particular biological study. Conversely, identifying a biologically relevant gene using the combined data method that cannot be identified in any single dataset, implies that the individual datasets are not reliable when examined alone. 
B. Biological Validation
We examine the significant genes that we discover from the Dhanasekaran, Luo, Magee, and Welsh prostate cancer datasets and compare the gene lists from the combined dataset to those of the individual datasets. While the numbers of significant genes listed in Table II look similar between DS3 and the combined dataset, there is a difference in the gene lists as illustrated in Table IV and Table V . Even with the similarities between DS3 and the combined dataset, utilizing the combination method allows us to identify crucial significant genes that are not obvious in datasets like DS1, DS2, and DS4.
Based on a literature search, we have found that CTGF (connective tissue growth factor) and RBM4 (RNA binding motif protein 4) have been shown to be differentially expressed in prostate cancer [18, 19] . Additionally, as reported by GeneCards, CR605334 (human mRNA for KIAA0356 gene) has been shown to be expressed in colon carcinoma and breast carcinoma, but not in prostate cancer. Genes found to be differentially expressed only in the combined results show differential expression in prostate cancer. Genes only found in individual datasets seem to be less significant in their prostate cancer differential expression. A more extensive literature search on the differentially expressed genes would further elucidate the effectiveness of our method. 
IV. CONCLUSION
Until microarray technology becomes standardized, we must develop statistical methods to handle small sample data. Standardization protocols are currently not well defined. However, the ideal scenario of standardization should allow us to compare quantitative measurements across different platforms. Regardless of standardization, microarrays are still subject to technological variance. Our proposed method is a possible solution to avoid technical bias by computing differential gene expression scores on distinct microarray groups, then combining these scores across multiple groups of microarrays. The bootstrap accurately estimates classification errors for genes of individual small datasets while the combination method favors genes with low dataset variance. The results of this method for several prostate and renal cancer datasets suggests that bootstrap meta-analysis increases the biological relevance of identified genes.
